{"transactions":[{"id":689708,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-10","kind":"grant","planned":false,"acquired":true,"shares":1324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F8","text":"These restricted share units were granted on August 10, 2026 and are scheduled to vest on May 22, 2027."}],"balance_after":1324,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1324},"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689707,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Share Units","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These restricted share units were granted on May 22, 2025 and vested on August 10, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"These restricted share units were granted on May 22, 2025 and vested on August 10, 2026."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1732},"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689706,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":67,"price":165.51,"value":11089.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $165.16 to $166.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":6162,"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689705,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":590,"price":164.47,"value":97037.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $164.16 to $165.1599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":6229,"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689704,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":97,"price":163.77,"value":15885.69,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $163.15 to $164.1499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":6819,"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689703,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-11","kind":"sale","planned":false,"acquired":false,"shares":87,"price":162.72,"value":14156.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sale reported represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted share units. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple aggregated transactions at prices within the range of $162.08 to $163.0799, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4."}],"balance_after":6916,"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":689702,"issuer":{"id":3439,"kind":"organization","name":"ICON PLC","symbol":"ICLR"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-08-12T20:47:30.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1732,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These restricted share units were granted on May 22, 2025 and vested on August 10, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer upon vesting, with a nominal conversion price equal to the par value of the ordinary shares (EUR 0.06) per underlying share automatically deducted from the reporting person's pay in connection with vesting."}],"balance_after":7003,"source":{"system":"sec-edgar","filing":"0001628280-26-056304","document":"wk-form4_1786567646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060955/000162828026056304/wk-form4_1786567646.xml","form_type":"4"}},{"id":737679,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T21:08:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-26-000221","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071726000221/form4.xml","form_type":"4"}},{"id":1109683,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:28:00.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":4.24,"expiration_date":"2035-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-25-000233","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071725000233/form4.xml","form_type":"4"}},{"id":1477168,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T22:46:29.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.12,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-24-000345","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071724000345/form4.xml","form_type":"4"}},{"id":1665741,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-31T21:25:19.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 30, 2024, subject to the Reporting Person continuing to provide Continuous Service (as defined in the 2020 Equity Incentive Plan) through such date. If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":1.64,"expiration_date":"2034-01-30","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-24-002477","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919124002477/doc4.xml","form_type":"4"}},{"id":1717712,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-08T21:05:43.000Z","date":"2023-12-06","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from December 6, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":1.64,"expiration_date":"2033-12-06","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000390","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000390/form4.xml","form_type":"4"}},{"id":1849368,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:58:17.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.49,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001610717-23-000185","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000185/form4.xml","form_type":"4"}},{"id":1891361,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-05-16T20:54:08.000Z","date":"2023-05-15","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.45,"value":24500.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001610717-23-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000161071723000041/form4.xml","form_type":"4"}},{"id":2082555,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-12-19T21:24:37.000Z","date":"2022-12-15","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of December 15, 2022.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":6000,"derivative":{"exercise_price":2.32,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-22-061908","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919122061908/doc4.xml","form_type":"4"}},{"id":2185516,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-15T22:39:12.000Z","date":"2022-08-11","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-twelfth (1/12th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.965,"expiration_date":"2032-08-11","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-016296","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761922016296/doc1.xml","form_type":"4"}},{"id":2227475,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-18T01:27:34.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":0.9899,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013139","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761922013139/doc1.xml","form_type":"4"}},{"id":2571885,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-13T20:56:13.000Z","date":"2021-09-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the first anniversary of the grant date."}],"balance_after":15000,"derivative":{"exercise_price":2.6,"expiration_date":"2031-09-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-017012","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761921017012/doc1.xml","form_type":"4"}},{"id":2647460,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T21:34:31.000Z","date":"2021-07-01","kind":"disposition_to_issuer","acquired":false,"shares":9683,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (as it may be amended from time to time) (the \"Merger Agreement\"), dated as of February 24, 2021, by and among the Issuer, ICON plc (\"ICON\"), ICON US Holdings Inc. (\"US HoldCo\") and Indigo Merger Sub, Inc., each share of the Issuer's common stock was converted into the right to receive from ICON, 0.4125 of one ordinary share of ICON, and, from US HoldCo, $80.00 in cash, without any interest thereon (collectively, the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each award of restricted stock of the Issuer that is outstanding immediately prior to the effective time of the merger was converted into the right to receive the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-088348","document":"tm2121280-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465921088348/tm2121280-3_4seq1.xml","form_type":"4"}},{"id":2666067,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-16T20:19:14.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":2.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-21-012197","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761921012197/doc1.xml","form_type":"4"}},{"id":2669989,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T01:36:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.9318,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001567619-21-012090","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761921012090/doc1.xml","form_type":"4"}},{"id":2669988,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-15T01:36:43.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units which vest in a single installment on the earlier of (i) the first anniversary of the grant date and (ii) immediately prior to the annual meeting in 2022 of the Issuer's stockholders, assuming continuous service through such vesting date."}],"balance_after":22500,"source":{"system":"sec-edgar","filing":"0001567619-21-012090","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761921012090/doc1.xml","form_type":"4"}},{"id":2682962,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-03T20:03:29.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock granted under the PRA Health Sciences, Inc. 2020 Stock Incentive Plan that will vest on June 1, 2022, subject to continued service on such date. Further, the grant shall vest in full upon a change in control as defined under the applicable award agreement."}],"balance_after":9683,"source":{"system":"sec-edgar","filing":"0001104659-21-076349","document":"tm2118302-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465921076349/tm2118302-4_4seq1.xml","form_type":"4"}},{"id":2908766,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-14T00:06:01.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan, vesting in 36 equal monthly installments beginning as of December 21, 2020.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":12000,"derivative":{"exercise_price":4.31,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-003470","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121003470/doc4.xml","form_type":"4"}},{"id":3097486,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-06-30T01:56:25.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units which vest in a single installment on the first anniversary of June 3, 2020, subject to the Reporting Person's continued service to the Issuer on\nthe vesting date."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001140361-20-015098","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000114036120015098/form4.xml","form_type":"4"}},{"id":3111645,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-12T21:10:30.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-012098","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761920012098/doc1.xml","form_type":"4"}},{"id":3120185,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T21:08:07.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":1.01,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-011812","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761920011812/doc1.xml","form_type":"4"}},{"id":3120186,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T21:07:26.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option shall vest on the first anniversary of the date of grant."}],"balance_after":15000,"derivative":{"exercise_price":1.01,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-011811","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761920011811/doc1.xml","form_type":"4"}},{"id":3140678,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-20T20:58:17.000Z","date":"2020-05-18","kind":"grant","acquired":true,"shares":1324,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock that will vest on the first anniversary of the grant date, subject to continued service on such date."}],"balance_after":9433,"source":{"system":"sec-edgar","filing":"0001104659-20-064310","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465920064310/a4.xml","form_type":"4"}},{"id":3197831,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-23T21:31:13.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest and become exercisable on the one-year anniversary of the grant date, subject to continued service as a director through such date."}],"balance_after":15000,"derivative":{"exercise_price":2,"expiration_date":"2030-03-19","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-20-006910","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761920006910/doc1.xml","form_type":"4"}},{"id":3479980,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-24T20:05:51.000Z","date":"2019-06-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.61,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017917","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924319017917/doc4.xml","form_type":"4"}},{"id":3500374,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-05T21:04:05.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":1436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock that will vest on the first anniversary of the grant date, subject to continued service on such date."}],"balance_after":8109,"source":{"system":"sec-edgar","filing":"0001104659-19-034066","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465919034066/a4.xml","form_type":"4"}},{"id":3682561,"issuer":{"id":4839,"kind":"organization","name":"Corvus Pharmaceuticals, Inc."},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-30T21:08:25.000Z","date":"2019-01-28","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from January 28, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":3.88,"expiration_date":"2029-01-28","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-19-002194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924319002194/doc4.xml","form_type":"4"}},{"id":3694499,"issuer":{"id":12518,"kind":"organization","name":"Zosano Pharma Corp","symbol":"ZSAN"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-17T00:19:47.000Z","date":"2019-01-14","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total number of shares underlying the stock option vest on January 14, 2019, and the remaining underlying shares vest in equal monthly installments over the following three-year period."}],"balance_after":25000,"derivative":{"exercise_price":2.56,"expiration_date":"2029-01-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001567619-19-001255","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000156761919001255/doc1.xml","form_type":"4"}},{"id":3883988,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-25T20:06:01.000Z","date":"2018-06-21","kind":"grant","acquired":true,"shares":1307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock which will vest fifty percent on each of the first two anniversaries of the grant date, subject to continued service on such dates."}],"balance_after":6673,"source":{"system":"sec-edgar","filing":"0001104659-18-042049","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465918042049/a4.xml","form_type":"4"}},{"id":4017300,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-05T22:34:08.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2018.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":0.72,"expiration_date":"2028-02-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-18-016691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919118016691/doc4.xml","form_type":"4"}},{"id":4136324,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":11969,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"This In the Money Option, which became fully vested on July 16, 2011, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"This In the Money Option, which became fully vested on July 16, 2011, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.67,"expiration_date":"2021-06-16","underlying":"Common Stock","underlying_shares":11969},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136323,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":30827,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"This In the Money Option, which became fully vested on July 15, 2013, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"This In the Money Option, which became fully vested on July 15, 2013, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.67,"expiration_date":"2022-06-13","underlying":"Common Stock","underlying_shares":30827},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136322,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":30826,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"This In the Money Option, which became fully vested on August 7, 2013, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"This In the Money Option, which became fully vested on August 7, 2013, was cancelled in connection with the Merger in exchange for the right to receive (i) a cash payment, without interest and subject to deduction for any required withholding taxes, equal to (A) the excess, if any, of (x) the Closing Amount over (y) the exercise price payable per Share under such In the Money Option, multiplied by (B) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time and (ii) a CVR with respect to the total number of Shares subject to such In the Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.67,"expiration_date":"2022-06-13","underlying":"Common Stock","underlying_shares":30826},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136321,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":37500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 11, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 11, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.84,"expiration_date":"2024-06-11","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136320,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":491550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on August 13, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on August 13, 2015, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger for no consideration"}],"balance_after":0,"derivative":{"exercise_price":7.38,"expiration_date":"2023-08-13","underlying":"Common Stock","underlying_shares":491550},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136319,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":160000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 18, 2017, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on June 18, 2017, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.76,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136318,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":348600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on February 6, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on February 6, 2016, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.98, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.98,"expiration_date":"2026-01-05","underlying":"Common Stock","underlying_shares":348600},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136317,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":289200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on January 15, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.15, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4) All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Out of the Money Option, which provided for vesting in 48 equal monthly installments beginning on January 15, 2017, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.15, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.15,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":289200},"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136316,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":70000,"price":1.52,"value":106400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4136315,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-11T20:25:38.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":230000,"price":1.52,"value":349600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028424","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000089924317028424/doc4.xml","form_type":"4"}},{"id":4257100,"issuer":{"id":15912,"kind":"organization","name":"PRA Health Sciences, Inc.","symbol":"PRAH"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-14T20:05:20.000Z","date":"2017-07-12","kind":"grant","acquired":true,"shares":1318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock which will vest fifty percent on each of the first two anniversaries of the grant date, subject to continued service on such dates."}],"balance_after":5366,"source":{"system":"sec-edgar","filing":"0001104659-17-045045","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000110465917045045/a4.xml","form_type":"4"}},{"id":4368086,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-03-30T21:15:48.000Z","date":"2017-03-29","kind":"grant","acquired":true,"shares":230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.  50% of the RSUs shall vest on December 31, 2017, if the recipient is employed by or providing services to the Issuer on such date, and the remaining 50% of the RSUs shall vest on December 31, 2018, if the recipient is employed by or providing services to the Issuer on such date."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001274644-17-000021","document":"wf-form4_149090853361731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000127464417000021/wf-form4_149090853361731.xml","form_type":"4"}},{"id":4437404,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-02-21T22:24:55.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2013 Amended and Restated Equity Incentive Plan, vesting in 12 equal monthly installments beginning as of January 1, 2017.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested."}],"balance_after":8000,"derivative":{"exercise_price":2.5,"expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-012803","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117012803/doc4.xml","form_type":"4"}},{"id":4518740,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2016-12-16T21:40:17.000Z","date":"2016-12-15","kind":"grant","acquired":true,"shares":289200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Fourth Amended and Restated 2011 Stock Option and Incentive Plan (the \"Plan\"), qualified under Rule 16b-3(d)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in 48 equal monthly installments beginning on January 15, 2017, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":289200,"derivative":{"exercise_price":2.15,"expiration_date":"2026-12-14","underlying":"Common Stock","underlying_shares":289200},"source":{"system":"sec-edgar","filing":"0001274644-16-000163","document":"wf-form4_148192440453402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000127464416000163/wf-form4_148192440453402.xml","form_type":"4"}},{"id":4528601,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":24296,"kind":"person","name":"Grais Linda","position":1,"cik":"0001413306","reported_name":"Grais Linda S","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2016-12-08T21:18:54.000Z","date":"2016-12-07","kind":"purchase","acquired":true,"shares":7000,"price":2.14,"value":14980.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average price for the shares. The shares were purchased at prices ranging from $2.14 per share to $2.15 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001274644-16-000154","document":"wf-form4_148123192036284.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1413306/000127464416000154/wf-form4_148123192036284.xml","form_type":"4"}}]}